Efinopegdutide: Uses, Benefits & Research

What is Efinopegdutide?

Efinopegdutide (MK-6024) is a PEGylated synthetic peptide that acts as a dual GLP-1 and glucagon receptor co-agonist. Developed by Merck & Co. (MSD outside the US) in partnership with Hanmi Pharmaceutical, it is designed for once-weekly subcutaneous injection with an estimated molecular weight of 4,000-5,000 Da.

The dual co-agonist approach is the key differentiator: while most GLP-1 drugs activate only the GLP-1 receptor, efinopegdutide additionally activates glucagon receptors, which may enhance hepatic lipid metabolism and energy expenditure — particularly relevant for fatty liver disease.

Efinopegdutide remains investigational in Phase 2 development with no FDA approval as of March 2026.

Mechanism of Action

Efinopegdutide’s dual mechanism provides complementary metabolic effects:

GLP-1 receptor activation:

• Glucose-dependent insulin secretion from pancreatic beta cells
• Glucagon suppression to reduce hepatic glucose output
• Gastric emptying delay for satiety
• Central appetite reduction

Glucagon receptor activation:

• Enhanced hepatic lipid oxidation — promotes fat burning in the liver
• Increased energy expenditure
• Direct effects on liver lipid metabolism

This dual mechanism may explain the Phase 2a finding that efinopegdutide reduced liver fat by 72.7% compared to semaglutide’s 42.3% — the glucagon component provides liver-specific metabolic benefits that GLP-1 monotherapy does not.

Clinical Evidence

Human Studies

• Phase 2a NAFLD trial (PMID: 37355043): Randomized, active-comparator-controlled trial in patients with NAFLD. Efinopegdutide 10 mg weekly achieved 72.7% reduction in liver fat content at 24 weeks vs 42.3% with semaglutide 1 mg weekly — a statistically significant difference. Published in Nature Medicine (2023).
• Phase 2b trials (NCT06386628, NCT06592068): Currently recruiting to evaluate both weekly and bi-weekly dosing in NAFLD/MASH populations. Primary endpoint: relative reduction in liver fat content at 28 weeks.

Preclinical

Preclinical studies demonstrated dual GLP-1R and glucagon receptor agonist activity, enhanced liver fat reduction in NAFLD animal models versus GLP-1 monotherapy, and acceptable safety in preclinical toxicology.

Drug Interactions & Contraindications

No formal drug interaction studies have been published. Theoretical interactions derive from the dual receptor mechanism:

• Insulin/sulfonylureas: Additive hypoglycemic risk via GLP-1R activation
• Glucagon analogs: Additive glucagon receptor effects
• Oral medications: Delayed gastric emptying may affect absorption timing

Contraindicated per GLP-1 class precautions in patients with medullary thyroid carcinoma history or MEN 2. Unknown safety in decompensated liver disease.

Safety & Side Effects

Phase 2a adverse events were primarily gastrointestinal: nausea, diarrhea, and vomiting, consistent with the GLP-1 class. Notably, GI adverse event rates were slightly higher than with semaglutide, though described as manageable. No new safety signals were reported. Theoretical concerns specific to the glucagon component include hyperglucagonemia and hepatic safety effects requiring monitoring.

Honest Bottom Line

Efinopegdutide’s headline result — 72.7% liver fat reduction vs semaglutide’s 42.3% in Phase 2a — is the most compelling evidence that dual GLP-1/glucagon co-agonism may provide meaningful liver-specific benefits beyond GLP-1 monotherapy. This positions it as a potentially differentiated therapy for NAFLD/MASH. However, this is a single Phase 2a trial, and confirmation in the ongoing Phase 2b studies is essential. The evidence base (~3-5 RCTs) is early-stage, long-term safety is unknown, and no regulatory approval exists. Efinopegdutide competes with survodutide and tirzepatide in the MASH development pipeline. For patients with fatty liver disease, this is an emerging option to monitor, not a current treatment choice.